Welcome to our dedicated page for Editas Medicine news (Ticker: EDIT), a resource for investors and traders seeking the latest updates and insights on Editas Medicine stock.
Editas Medicine, Inc. (Nasdaq: EDIT) is a clinical-stage gene editing company that regularly issues news and updates about its in vivo CRISPR-based pipeline. Company announcements emphasize the development of transformative in vivo medicines using CRISPR/Cas12a and CRISPR/Cas9 systems, proprietary targeted lipid nanoparticle delivery, and a differentiated gene upregulation strategy applied to serious diseases.
News about Editas Medicine frequently covers progress with its lead in vivo development candidate, EDIT-401, an LDLR-targeted gene editing medicine designed to treat hyperlipidemia by increasing LDL receptor expression and reducing LDL cholesterol (LDL-C) levels. Recent releases have described preclinical proof-of-concept data in non-human primates and mice, showing approximately 90% or greater reductions in LDL-C after a single dose, as well as presentations at major scientific meetings such as the European Society of Gene and Cell Therapy Congress and the American Heart Association Scientific Sessions.
Investors and followers of EDIT can also expect updates on Editas’ in vivo hematopoietic stem cell program for sickle cell disease and beta thalassemia, including data on HBG1/2 promoter editing, fetal hemoglobin upregulation, and targeted lipid nanoparticle delivery in humanized mice and non-human primates. Additional news items highlight in vivo proof-of-concept for undisclosed liver targets, conference presentations at ASGCT, EHA, and TIDES, and participation in healthcare and investor conferences.
Financial news from Editas Medicine includes quarterly results, collaboration milestones such as the CD19 HD allogeneic CAR T program with Bristol Myers Squibb, and updates on cash runway supported by cash, marketable securities, at-the-market equity proceeds, and payments under its license agreement with Vertex Pharmaceuticals. This news page helps readers follow how scientific data, regulatory plans, collaborations, and financial developments shape the EDIT investment story over time.
On June 26, 2020, Editas Medicine (Nasdaq: EDIT) announced the completion of its underwritten public offering, selling 6,900,000 shares of common stock at a price of $31.25 per share. The offering generated approximately $215.6 million in gross proceeds, which includes 900,000 shares sold due to underwriter options. The registration statement related to the offering has been filed and is effective with the SEC. Morgan Stanley acted as the sole book-running manager for this offering.
Editas Medicine has announced an underwritten offering of 6,000,000 shares of its common stock at a price of $31.25 per share, aiming for gross proceeds of approximately $187.5 million. The offering features a 30-day option for underwriters to purchase an additional 900,000 shares. Scheduled to close around June 26, 2020, this transaction is being managed by Morgan Stanley and follows a Form S-3 registration with the SEC.
Editas Medicine (Nasdaq: EDIT) announced plans to offer 4,000,000 shares of common stock in a public offering, with the potential to sell an additional 600,000 shares. The offering will be managed by Morgan Stanley and is subject to market conditions. A registration statement has been filed with the SEC, and the offering details will be available through the final prospectus. Editas aims to utilize the funds to advance its CRISPR-based therapeutic pipeline targeting serious diseases. The offering carries uncertainties regarding completion and final terms.
Editas Medicine (Nasdaq: EDIT) announced promising results from a pre-clinical study of EDIT-301, a gene therapy aimed at treating sickle cell disease. The study showcased a high editing efficiency of approximately 90% in both in vitro and in vivo settings. Additionally, red blood cells derived from EDIT-301 demonstrated over 50% fetal hemoglobin (HbF) expression and significant improvements in cell deformability, indicating potential clinical benefits. The company aims to file an IND for EDIT-301 by the year's end, marking a pivotal step in its development.
Editas Medicine (Nasdaq: EDIT) announced results from a pre-clinical study showcasing the efficacy of its engineered CRISPR-Cas12a technology in iPSC-derived natural killer (iNK) cells for treating solid tumor cancers. The study, presented virtually at the 23rd ASGCT Annual Meeting, demonstrated that edited iNK cells exhibited enhanced tumor-killing activity compared to unedited counterparts. Editas is advancing its oncology programs, including IND-enabling studies for its HDNK engineered cell medicine and collaborations for T cell therapies.
Summary not available.
Summary not available.